Treatment-Resistant Bipolar Depression: Therapeutic Trends, Challenges and Future Directions

References

• Clemente AS, Diniz BS, Nicolato R, et al. Bipolar disorder prevalence: a systematic review and meta-analysis of the literature. Braz J Psychiatry. 2015;37(2):155–161. doi:10.1590/1516-4446-2012-1693
   PubMed Web of Science ®Google Scholar
• Burdick KE, Millett CE, Yocum AK, et al. Predictors of functional impairment in bipolar disorder: results from 13 cohorts from seven countries by the global bipolar cohort collaborative. Bipolar Disord. 2022;24(7):709–719. doi:10.1111/bdi.13208
   PubMed Web of Science ®Google Scholar
• Gardner HH, Kleinman NL, Brook RA, Rajagopalan K, Brizee TJ, Smeeding JE. The economic impact of bipolar disorder in an employed population from an employer perspective. J Clin Psychiatry. 2006;67(8):1209–1218. doi:10.4088/JCP.v67n0806
   PubMed Web of Science ®Google Scholar
• Altshuler LL, Post RM, Black DO, et al. Subsyndromal depressive symptoms are associated with functional impairment in patients with bipolar disorder: results of a large, multisite study. J Clin Psychiatry. 2006;67(10):1551–1560. doi:10.4088/JCP.v67n1009
   Web of Science ®Google Scholar
• Kupka RW, Altshuler LL, Nolen WA, et al. Three times more days depressed than manic or hypomanic in both bipolar I and bipolar II disorder. Bipolar Disord. 2007;9(5):531–535. doi:10.1111/j.1399-5618.2007.00467.x
   PubMed Web of Science ®Google Scholar
• Mendlewicz J, Massat I, Linotte S, et al. Identification of clinical factors associated with resistance to antidepressants in bipolar depression: results from an European Multicentre Study. Int Clin Psychopharmacol. 2010;25(5):297–301. doi:10.1097/YIC.0b013e32833c4ceb
   Web of Science ®Google Scholar
• Yatham LN, Kennedy SH, Parikh SV, et al. Canadian network for mood and anxiety treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord. 2018;20(2):97–170. doi:10.1111/bdi.12609
   PubMed Web of Science ®Google Scholar
• Park JH, Nunez NA, Gardea-Resendez M, et al. Short term second-generation antidepressant monotherapy in acute depressive episodes of bipolar II disorder: a systematic review and meta-analysis. Psychopharmacol Bull. 2022;52(2):45–72.
   Google Scholar
• Sachs GS. Treatment-resistant bipolar depression. Psychiatr Clin North Am. 1996;19(2):215–236. doi:10.1016/S0193-953X(05)70285-9
   PubMed Web of Science ®Google Scholar
• Yatham LN, Calabrese JR, Kusumakar V. Bipolar depression: criteria for treatment selection, definition of refractoriness, and treatment options. Bipolar Disord. 2003;5(2):85–97. doi:10.1034/j.1399-5618.2003.00019.x
   PubMed Web of Science ®Google Scholar
• Nierenberg AA, Ostacher MJ, Calabrese JR, et al. Treatment-resistant bipolar depression: a STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidone. Am J Psychiatry. 2006;163(2):210–216. doi:10.1176/appi.ajp.163.2.210
   PubMed Web of Science ®Google Scholar
• Gitlin M. Treatment-resistant bipolar disorder. Mol Psychiatry. 2006;11(3):227–240. doi:10.1038/sj.mp.4001793
   PubMed Web of Science ®Google Scholar
• Gajwani P. Treatment-refractory bipolar disorder: classification to aid in clinical management. Expert Opin Pharmacother. 2009;10(12):1907–1915. doi:10.1517/14656560903064170
   PubMed Web of Science ®Google Scholar
• Pacchiarotti I, Mazzarini L, Colom F, et al. Treatment-resistant bipolar depression: towards a new definition. Acta Psychiatr Scand. 2009;120(6):429–440. doi:10.1111/j.1600-0447.2009.01471.x
   PubMed Web of Science ®Google Scholar
• Lipsman N, McIntyre RS, Giacobbe P, Torres C, Kennedy SH, Lozano AM. Neurosurgical treatment of bipolar depression: defining treatment resistance and identifying surgical targets. Bipolar Disord. 2010;12(7):691–701. doi:10.1111/j.1399-5618.2010.00868.x
   PubMed Web of Science ®Google Scholar
• Malhi GS, Bargh DM, Cashman E, Frye MA, Gitlin M. The clinical management of bipolar disorder complexity using a stratified model. Bipolar Disord. 2012;14(Suppl 2):66–89. doi:10.1111/j.1399-5618.2012.00993.x
   Web of Science ®Google Scholar
• Poon SH, Sim K, Sum MY, Kuswanto, CN, Baldessarini, RJ. Evidence-based options for treatment-resistant adult bipolar disorder patients. Bipolar Disord. 2012;14(6):573–584. doi:10.1111/j.1399-5618.2012.01042.x.
   Web of Science ®Google Scholar
• Hidalgo-Mazzei D, Berk M, Cipriani A, et al. Treatment-resistant and multi-therapy-resistant criteria for bipolar depression: consensus definition. Br J Psychiatry. 2019;214(1):27–35. doi:10.1192/bjp.2018.257
   Web of Science ®Google Scholar
• Fountoulakis KN, Yatham LN, Grunze H, et al. The CINP guidelines on the definition and evidence-based interventions for treatment-resistant bipolar disorder. Int J Neuropsychopharmacol. 2020;23(4):230–256. doi:10.1093/ijnp/pyz064
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Practice Guideline for the Treatment of Patients with Bipolar Disorder (Revision). American Psychiatric Pub; 2002.
   Google Scholar
• Grunze H, Vieta E, Goodwin GM, et al. The world federation of societies of biological psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2010 on the treatment of acute bipolar depression. World J Biol Psychiatry. 2010;11(2):81–109. doi:10.3109/15622970903555881
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence (NICE). National institute for health and care excellence: guidelines. In: Bipolar Disorder: Assessment and Management. London: National Institute for Health and Care Excellence (NICE) Copyright © NICE 2019; 2018.
   Google Scholar
• Goodwin GM, Haddad PM, Ferrier IN, et al. Evidence-based guidelines for treating bipolar disorder: revised third edition recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2016;30(6):495–553. doi:10.1177/0269881116636545
   PubMed Web of Science ®Google Scholar
• Malhi GS, Bell E, Bassett D, et al. The 2020 royal Australian and New Zealand college of psychiatrists clinical practice guidelines for mood disorders. Aust N Z J Psychiatry. 2021;55(1):7–117. doi:10.1177/0004867420979353
   PubMed Web of Science ®Google Scholar
• van der Loos ML, Mulder PG, Hartong EG, et al. Efficacy and safety of lamotrigine as add-on treatment to lithium in bipolar depression: a multicenter, double-blind, placebo-controlled trial. J Clin Psychiatry. 2009;70(2):223–231. doi:10.4088/JCP.08m04152
   PubMed Web of Science ®Google Scholar
• Frye MA, Ketter TA, Kimbrell TA, et al. A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. J Clin Psychopharmacol. 2000;20(6):607–614. doi:10.1097/00004714-200012000-00004
   PubMed Web of Science ®Google Scholar
• van der Loos ML, Mulder P, Hartong EG, et al. Efficacy and safety of two treatment algorithms in bipolar depression consisting of a combination of lithium, lamotrigine or placebo and paroxetine. Acta Psychiatr Scand. 2010;122(3):246–254. doi:10.1111/j.1600-0447.2009.01537.x
   PubMed Web of Science ®Google Scholar
• Bocchetta A, Bernardi F, Burrai C, Pedditzi M, Del Zompo M. A double-blind study of L-sulpiride versus amitriptyline in lithium-maintained bipolar depressives. Acta Psychiatr Scand. 1993;88(6):434–439. doi:10.1111/j.1600-0447.1993.tb03487.x
   Web of Science ®Google Scholar
• Loebel A, Cucchiaro J, Silva R, et al. Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am J Psychiatry. 2014;171(2):160–168. doi:10.1176/appi.ajp.2013.13070984
   PubMed Web of Science ®Google Scholar
• Nemeroff CB, Evans DL, Gyulai L, et al. Double-blind, placebo-controlled comparison of imipramine and paroxetine in the treatment of bipolar depression. Am J Psychiatry. 2001;158(6):906–912. doi:10.1176/appi.ajp.158.6.906
   PubMed Web of Science ®Google Scholar
• Sachs GS, Ice K, Chappell P. Efficacy and safety of adjunctive oral ziprasidone for acute treatment of depression in patients with bipolar I disorder. J Clin Psychiatry. 2011;72(10):1413–1422. doi:10.4088/JCP.09m05934
   PubMed Web of Science ®Google Scholar
• Goldberg JF, Burdick KE, Endick CJ. Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression. Am J Psychiatry. 2004;161(3):564–566. doi:10.1176/appi.ajp.161.3.564
   PubMed Web of Science ®Google Scholar
• Murphy BL, Ravichandran C, Babb SM, Cohen BM. Naltrexone in bipolar disorder with depression: a double-blind, placebo-controlled study. J Clin Psychopharmacol. 2014;34(6):749–751. doi:10.1097/JCP.0000000000000222
   Web of Science ®Google Scholar
• Nunez NA, Singh B, Romo-Nava F, et al. Efficacy and tolerability of adjunctive modafinil/armodafinil in bipolar depression: a meta-analysis of randomized controlled trials. Bipolar Disord. 2020;22(2):109–120. doi:10.1111/bdi.12859
   Web of Science ®Google Scholar
• Frye MA, Grunze H, Suppes T, et al. A placebo-controlled evaluation of adjunctive modafinil in the treatment of bipolar depression. Am J Psychiatry. 2007;164(8):1242–1249. doi:10.1176/appi.ajp.2007.06060981
   PubMed Web of Science ®Google Scholar
• Calabrese JR, Ketter TA, Youakim JM, Tiller JM, Yang R, Frye MA. Adjunctive armodafinil for major depressive episodes associated with bipolar I disorder: a randomized, multicenter, double-blind, placebo-controlled, proof-of-concept study. J Clin Psychiatry. 2010;71(10):1363–1370. doi:10.4088/JCP.09m05900gry
   PubMed Web of Science ®Google Scholar
• Calabrese JR, Frye MA, Yang R, Ketter TA. Efficacy and safety of adjunctive armodafinil in adults with major depressive episodes associated with bipolar I disorder: a randomized, double-blind, placebo-controlled, multicenter trial. J Clin Psychiatry. 2014;75(10):1054–1061. doi:10.4088/JCP.13m08951
   PubMed Web of Science ®Google Scholar
• Ketter TA, Yang R, Frye MA. Adjunctive armodafinil for major depressive episodes associated with bipolar I disorder. J Affect Disord. 2015;181:87–91. doi:10.1016/j.jad.2015.04.012
   PubMed Web of Science ®Google Scholar
• Halaris A, Cantos A, Johnson K, Hakimi M, Sinacore J. Modulation of the inflammatory response benefits treatment-resistant bipolar depression: a randomized clinical trial. J Affect Disord. 2020;261:145–152. doi:10.1016/j.jad.2019.10.021
   PubMed Web of Science ®Google Scholar
• Calkin CV, Chengappa KNR, Cairns K, et al. Treating insulin resistance with metformin as a strategy to improve clinical outcomes in treatment-resistant bipolar depression (the TRIO-BD Study): a randomized, quadruple-masked, placebo-controlled clinical trial. J Clin Psychiatry. 2022;83:2. doi:10.4088/JCP.21m14022
   Web of Science ®Google Scholar
• Zeinoddini A, Sorayani M, Hassanzadeh E, et al. Pioglitazone adjunctive therapy for depressive episode of bipolar disorder: a randomized, double-blind, placebo-controlled trial. Depress Anxiety. 2015;32(3):167–173. doi:10.1002/da.22340
   PubMed Web of Science ®Google Scholar
• Aftab A, Kemp DE, Ganocy SJ, et al. Double-blind, placebo-controlled trial of pioglitazone for bipolar depression. J Affect Disord. 2019;245:957–964. doi:10.1016/j.jad.2018.11.090
   PubMed Web of Science ®Google Scholar
• Fries GR, Walss-Bass C, Bauer ME, Teixeira AL. Revisiting inflammation in bipolar disorder. Pharmacol Biochem Behav. 2019;177:12–19. doi:10.1016/j.pbb.2018.12.006
   PubMed Web of Science ®Google Scholar
• Kohler-Forsberg O, Hjorthoj C, Nordentoft M, Mors O, Benros ME. Efficacy of anti-inflammatory treatment on major depressive disorder or depressive symptoms: meta-analysis of clinical trials. Acta Psychiatr Scand. 2019;139(5):404–419. doi:10.1111/acps.13016
   PubMed Web of Science ®Google Scholar
• Castillo MFR, Cohen A, Edberg D, et al. Vascular endothelial growth factor in bipolar depression: a potential biomarker for diagnosis and treatment outcome prediction. Psychiatry Res. 2020;284:112781. doi:10.1016/j.psychres.2020.112781
   PubMed Web of Science ®Google Scholar
• Edberg D, Hoppensteadt D, Walborn A, Fareed J, Sinacore J, Halaris A. Plasma C-reactive protein levels in bipolar depression during cyclooxygenase-2 inhibitor combination treatment. J Psychiatr Res. 2018;102:1–7. doi:10.1016/j.jpsychires.2018.02.004
   PubMed Web of Science ®Google Scholar
• Edberg D, Hoppensteadt D, Walborn A, Fareed J, Sinacore J, Halaris A. Plasma MCP-1 levels in bipolar depression during cyclooxygenase-2 inhibitor combination treatment. J Psychiatr Res. 2020;129:189–197. doi:10.1016/j.jpsychires.2020.06.010
   Web of Science ®Google Scholar
• Calkin CV, Ruzickova M, Uher R, et al. Insulin resistance and outcome in bipolar disorder. Br J Psychiatry. 2015;206(1):52–57. doi:10.1192/bjp.bp.114.152850
   PubMed Web of Science ®Google Scholar
• Singh B, Sundaresh V. Thyroid hormone use in mood disorders: revisiting the evidence. J Clin Psychiatry. 2022;83:5. doi:10.4088/JCP.22ac14590
   Web of Science ®Google Scholar
• Kelly T, Lieberman DZ. The use of triiodothyronine as an augmentation agent in treatment-resistant bipolar II and bipolar disorder NOS. J Affect Disord. 2009;116(3):222–226. doi:10.1016/j.jad.2008.12.010
   Web of Science ®Google Scholar
• Law AJ, Deakin JF. Asymmetrical reductions of hippocampal NMDAR1 glutamate receptor mRNA in the psychoses. Neuroreport. 2001;12(13):2971–2974. doi:10.1097/00001756-200109170-00043
   PubMed Web of Science ®Google Scholar
• McCullumsmith RE, Kristiansen LV, Beneyto M, Scarr E, Dean B, Meador-Woodruff JH. Decreased NR1, NR2A, and SAP102 transcript expression in the hippocampus in bipolar disorder. Brain Res. 2007;1127(1):108–118. doi:10.1016/j.brainres.2006.09.011
   Web of Science ®Google Scholar
• Woo TU, Walsh JP, Benes FM. Density of glutamic acid decarboxylase 67 messenger RNA-containing neurons that express the N-methyl-D-aspartate receptor subunit NR2A in the anterior cingulate cortex in schizophrenia and bipolar disorder. Arch Gen Psychiatry. 2004;61(7):649–657. doi:10.1001/archpsyc.61.7.649
   Web of Science ®Google Scholar
• Brennan BP, Hudson JI, Jensen JE, et al. Rapid enhancement of glutamatergic neurotransmission in bipolar depression following treatment with riluzole. Neuropsychopharmacology. 2010;35(3):834–846. doi:10.1038/npp.2009.191
   PubMed Web of Science ®Google Scholar
• Zarate CA, Quiroz JA, Singh JB, et al. An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression. Biol Psychiatry. 2005;57(4):430–432. doi:10.1016/j.biopsych.2004.11.023
   PubMed Web of Science ®Google Scholar
• Sanacora G, Frye MA, McDonald, W. American Psychiatric Association (APA) Council of Research Task Force on Novel Biomarkers and Treatments. A consensus statement on the use of ketamine in the treatment of mood disorders. JAMA Psychiatry. 2017;74(4):399–405. doi:10.1001/jamapsychiatry.2017.0080
   PubMed Web of Science ®Google Scholar
• Gao M, Rejaei D, Liu H. Ketamine use in current clinical practice. Acta Pharmacol Sin. 2016;37(7):865–872. doi:10.1038/aps.2016.5
   PubMed Web of Science ®Google Scholar
• Joseph B, Parsaik AK, Ahmed AT, Erwin PJ, Singh B. Systematic review on the efficacy of intravenous racemic ketamine for bipolar depression. J Clin Psychopharmacol. 2021. 41. 1:71–75. doi:10.1097/JCP.0000000000001317
   PubMed Web of Science ®Google Scholar
• Singh B, Vande Voort JL, Frye MA, Kung S. Can ketamine be a safe option for treatment-resistant bipolar depression? Expert Opin Drug Saf. 2022;21(6):717–720. doi:10.1080/14740338.2022.2045272
   PubMed Web of Science ®Google Scholar
• Canuso CM, Singh JB, Fedgchin M, et al. Efficacy and safety of intranasal esketamine for the rapid reduction of symptoms of depression and suicidality in patients at imminent risk for suicide: results of a double-blind, randomized, placebo-controlled study. Am J Psychiatry. 2018;175(7):620–630. doi:10.1176/appi.ajp.2018.17060720
   PubMed Web of Science ®Google Scholar
• Berman RM, Cappiello A, Anand A, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000;47(4):351–354. doi:10.1016/S0006-3223(99)00230-9
   PubMed Web of Science ®Google Scholar
• Diazgranados N, Ibrahim L, Brutsche NE, et al. A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry. 2010;67(8):793–802. doi:10.1001/archgenpsychiatry.2010.90
   PubMed Web of Science ®Google Scholar
• Zarate CA, Brutsche NE, Ibrahim L, et al. Replication of ketamine’s antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol Psychiatry. 2012;71(11):939–946. doi:10.1016/j.biopsych.2011.12.010
   PubMed Web of Science ®Google Scholar
• Xu AJ, Niciu MJ, Lundin NB, et al. Lithium and valproate levels do not correlate with ketamine’s antidepressant efficacy in treatment-resistant bipolar depression. Neural Plast. 2015;2015:858251. doi:10.1155/2015/858251
   PubMed Web of Science ®Google Scholar
• Lally N, Nugent AC, Luckenbaugh DA, Ameli R, Roiser JP, Zarate CA. Anti-anhedonic effect of ketamine and its neural correlates in treatment-resistant bipolar depression. Transl Psychiatry. 2014;4:e469. doi:10.1038/tp.2014.105
   PubMed Web of Science ®Google Scholar
• Saligan LN, Luckenbaugh DA, Slonena EE, Machado-Vieira R, Zarate CA. An assessment of the anti-fatigue effects of ketamine from a double-blind, placebo-controlled, crossover study in bipolar disorder. J Affect Disord. 2016;194:115–119. doi:10.1016/j.jad.2016.01.009
   PubMed Web of Science ®Google Scholar
• Villasenor A, Ramamoorthy A, Silva Dos Santos M, et al. A pilot study of plasma metabolomic patterns from patients treated with ketamine for bipolar depression: evidence for a response-related difference in mitochondrial networks. Br J Pharmacol. 2014;171(8):2230–2242. doi:10.1111/bph.12494
   Web of Science ®Google Scholar
• Zheng W, Zhou YL, Wang CY, et al. Neurocognitive effects of six ketamine infusions and the association with antidepressant effects in treatment-resistant bipolar depression: a preliminary study. PeerJ. 2020;8:e10208. doi:10.7717/peerj.10208
   Web of Science ®Google Scholar
• Singh B, Vande Voort JL, Kung S. Ketamine for treatment-resistant bipolar depression-need for more data! Bipolar Disord. 2021;23(7):728–729. doi:10.1111/bdi.13129
   Web of Science ®Google Scholar
• Murata S, Murphy M, Hoppensteadt D, Fareed J, Welborn A, Halaris A. Effects of adjunctive inflammatory modulation on IL-1beta in treatment resistant bipolar depression. Brain Behav Immun. 2020;87:369–376. doi:10.1016/j.bbi.2020.01.004
   PubMed Web of Science ®Google Scholar
• Wilkowska A, Wlodarczyk A, Galuszko-Wegielnik M, Wiglusz MS, Cubala WJ. Intravenous ketamine infusions in treatment-resistant bipolar depression: an open-label naturalistic observational study. Neuropsychiatr Dis Treat. 2021;17:2637–2646. doi:10.2147/NDT.S325000
   PubMed Web of Science ®Google Scholar
• Schoeyen HK, Kessler U, Andreassen OA, et al. Treatment-resistant bipolar depression: a randomized controlled trial of electroconvulsive therapy versus algorithm-based pharmacological treatment. Am J Psychiatry. 2015;172(1):41–51. doi:10.1176/appi.ajp.2014.13111517
   PubMed Web of Science ®Google Scholar
• Kessler U, Schoeyen HK, Andreassen OA, et al. The effect of electroconvulsive therapy on neurocognitive function in treatment-resistant bipolar disorder depression. J Clin Psychiatry. 2014;75(11):e1306–e1313. doi:10.4088/JCP.13m08960
   Web of Science ®Google Scholar
• Bjoerke-Bertheussen J, Schoeyen H, Andreassen OA, et al. Right unilateral electroconvulsive therapy does not cause more cognitive impairment than pharmacologic treatment in treatment-resistant bipolar depression: a 6-month randomized controlled trial follow-up study. Bipolar Disord. 2018;20(6):531–538. doi:10.1111/bdi.12594
   Web of Science ®Google Scholar
• Sienaert P, Vansteelandt K, Demyttenaere K, Peuskens J. Ultra-brief pulse ECT in bipolar and unipolar depressive disorder: differences in speed of response. Bipolar Disord. 2009;11(4):418–424. doi:10.1111/j.1399-5618.2009.00702.x
   Web of Science ®Google Scholar
• Bailine S, Fink M, Knapp R, et al. Electroconvulsive therapy is equally effective in unipolar and bipolar depression. Acta Psychiatr Scand. 2010;121(6):431–436. doi:10.1111/j.1600-0447.2009.01493.x
   Web of Science ®Google Scholar
• Fitzgerald PB, Hoy KE, Elliot D, McQueen S, Wambeek LE, Daskalakis ZJ. A negative double-blind controlled trial of sequential bilateral rTMS in the treatment of bipolar depression. J Affect Disord. 2016;198:158–162. doi:10.1016/j.jad.2016.03.052
   PubMed Web of Science ®Google Scholar
• Tavares DF, Myczkowski ML, Alberto RL, et al. Treatment of bipolar depression with deep TMS: results from a double-blind, randomized, parallel group, sham-controlled clinical trial. Neuropsychopharmacology. 2017;42(13):2593–2601. doi:10.1038/npp.2017.26
   PubMed Web of Science ®Google Scholar
• Kito S, Miyazi M, Nakatani H, et al. Effectiveness of high-frequency left prefrontal repetitive transcranial magnetic stimulation in patients with treatment-resistant depression: a randomized clinical trial of 37.5-minute vs 18.75-minute protocol. Neuropsychopharmacol Rep. 2019;39(3):203–208. doi:10.1002/npr2.12066
   PubMedGoogle Scholar
• Chen L, Thomas EHX, Kaewpijit P, et al. Accelerated theta burst stimulation for the treatment of depression: a randomised controlled trial. Brain Stimul. 2021;14(5):1095–1105. doi:10.1016/j.brs.2021.07.018
   Web of Science ®Google Scholar
• Rush AJ, Marangell LB, Sackeim HA, et al. Vagus nerve stimulation for treatment-resistant depression: a randomized, controlled acute phase trial. Biol Psychiatry. 2005;58(5):347–354. doi:10.1016/j.biopsych.2005.05.025
   PubMed Web of Science ®Google Scholar
• Nierenberg AA, Alpert JE, Gardner-Schuster EE, Seay S, Mischoulon D. Vagus nerve stimulation: 2-year outcomes for bipolar versus unipolar treatment-resistant depression. Biol Psychiatry. 2008;64(6):455–460. doi:10.1016/j.biopsych.2008.04.036
   PubMed Web of Science ®Google Scholar
• McAllister-Williams RH, Sousa S, Kumar A, et al. The effects of vagus nerve stimulation on the course and outcomes of patients with bipolar disorder in a treatment-resistant depressive episode: a 5-year prospective registry. Int J Bipolar Disord. 2020;8(1):13. doi:10.1186/s40345-020-0178-4
   Web of Science ®Google Scholar
• Holtzheimer PE, Kelley ME, Gross RE, et al. Subcallosal cingulate deep brain stimulation for treatment-resistant unipolar and bipolar depression. Arch Gen Psychiatry. 2012;69(2):150–158. doi:10.1001/archgenpsychiatry.2011.1456
   PubMed Web of Science ®Google Scholar
• Intra-Cellular Therapies I. Clinical trial evaluating lumateperone monotherapy in the treatment of bipolar depression or major depressive disorder; 2020. Available from: https://ClinicalTrials.gov/show/NCT04285515. Accessed December 8, 2022.
   Google Scholar
• University FAHoZ, University Z. Vortioxetine adjunctive treatment in bipolar depression; 2022. Available from: https://ClinicalTrials.gov/show/NCT05481957. Accessed December 8, 2022.
   Google Scholar
• Clinic M, Hope L. 8 week multi-site study of MYDAYIS® for bipolar depression; 2020. Available from: https://ClinicalTrials.gov/show/NCT04235686. Accessed December 8, 2022.
   Google Scholar
• Institute DMHU, University M, Hospital JG. Brexpiprazole treatment for bipolar I depression; 2021. Available from: https://ClinicalTrials.gov/show/NCT04569448. Accessed December 8, 2022.
   Google Scholar
• University Health Network T. Maintenance ketamine infusions for treatment-resistant bipolar depression; 2022. Available from: https://ClinicalTrials.gov/show/NCT05339074. Accessed December 8, 2022.
   Google Scholar
• Center SMH. Efficacy and safety of peropirone hydrochloride tablets in the treatment of adolescent bipolar disorder depression; 2020. Available from: https://ClinicalTrials.gov/show/NCT04826510. Accessed December 8, 2022.
   Google Scholar
• Clinic M. Ketamine associated ACC GABA and glutamate change and depression remission; 2019. Available from: https://ClinicalTrials.gov/show/NCT03573349. Accessed December 8, 2022.
   Google Scholar
• Consorcio Centro de Investigación Biomédica en Red MP, Institute SMR. Trehalose as add-on therapy in bipolar depression; 2016. Available from: https://ClinicalTrials.gov/show/NCT02800161. Accessed December 8, 2022.
   Google Scholar
• Fe IdISL, Medicines SAo, Products H, Fe HUL. Efficacy of TBS in treatment resistant depression; 2021. Available from: https://ClinicalTrials.gov/show/NCT04998773. Accessed December 8, 2022.
   Google Scholar
• Fitzgerald PB, Chen L, Richardson K, Daskalakis ZJ, Hoy KE. A pilot investigation of an intensive theta burst stimulation protocol for patients with treatment resistant depression. Brain Stimul. 2020;13(1):137–144.
   PubMed Web of Science ®Google Scholar
• Hallahan DB, Institute SMR, National University of Ireland G, Ireland, HRB Clinical Research Facility Galway I, Galway UCH. Scopolamine in bipolar depression; 2021. Available form: https://ClinicalTrials.gov/show/NCT04211961. Accessed December 8, 2022.
   Google Scholar
• Health NIoM, Center NIoHC. Transcranial Electric Stimulation Therapy (TEST) for Treatment Resistant Depression (TRD; 2022. Available from: https://ClinicalTrials.gov/show/NCT05172271. Accessed December 8, 2022.
   Google Scholar
• Hospital MG. Xenon inhalation therapy for major depressive disorder and bipolar disorder; 2019. Available from: https://ClinicalTrials.gov/show/NCT03748446. Accessed December 8, 2022.
   Google Scholar
• Hospital MG, Brain, Foundation BR, Willard J, Foundation ASM. BezafibrateTreatment for Bipolar Depression: a Proof of Concept Study; 2015. Available from: https://ClinicalTrials.gov/show/NCT02481245. Accessed December 8, 2022.
   Google Scholar
• Janssen Pharmaceutica N.V. B. A Study of JNJ-55308942 in the treatment of bipolar depression; 2022. Available from: https://ClinicalTrials.gov/show/NCT05328297. Accessed December 8, 2022.
   Google Scholar
• Kong CUoH. Adjunctive bright light therapy in patients with bipolar depression and eveningness; 2022. Available from: https://ClinicalTrials.gov/show/NCT05357313. Accessed December 8, 2022.
   Google Scholar
• Korea Otsuka Pharmaceutical Co. A study of abilify® tablet (aripiprazole) as an adjunctive treatment in the bipolar depression; 2018. Available from: https://ClinicalTrials.gov/show/NCT03423680. Accessed December 8, 2022.
   Google Scholar
• NeuroRx I, Prevail Infoworks I. NRX101 for bipolar depression and sub-acute suicidal ideation and behavior; 2022. Available from: https://ClinicalTrials.gov/show/NCT03395392. Accessed December 8, 2022.
   Google Scholar
• Paris AP-Hd, Pharma I. Low dose IL-2 therapy in patients with a depressive episode in the course of a bipolar disorder; 2020. Available from: https://ClinicalTrials.gov/show/NCT04133233. Accessed December 8, 2022.
   Google Scholar
• Paulo UoS. Creatine monohydrate as adjuvant therapy for bipolar depression; 2012. Available from: https://ClinicalTrials.gov/show/NCT01655030. Accessed December 8, 2022.
   Google Scholar
• Paulo UoS, Paulo FdAàPdEdS. Electro-magnetic convulsive therapies for depression: a non-inferiority study; 2021. Available from: https://ClinicalTrials.gov/show/NCT05054699. Accessed December 8, 2022.
   Google Scholar
• Pennsylvania Uo. Intensive TMS for bipolar depression; 2022. Available from: https://ClinicalTrials.gov/show/NCT05228457. Accessed December 8, 2022.
   Google Scholar
• Sunovion. A clinical study of an investigational drug for the treatment of major depressive episode associated with bipolar I disorder; 2021. Available from: https://ClinicalTrials.gov/show/NCT05169710. Accessed December 8, 2022.
   Google Scholar
• Taylor V, University Health Network T, Hospital WsC. Safety and efficacy of fecal microbiota transplantation in a population with bipolar disorder; 2018. Available from: https://ClinicalTrials.gov/show/NCT03279224. Accessed December 8, 2022.
   Google Scholar
• The University of Texas Health Science Center H. Adjunctive allogeneic mesenchymal stem cells for treatment-resistant bipolar depression; 2021. Available from: https://ClinicalTrials.gov/show/NCT03522545. Accessed December 8, 2022.
   Google Scholar
• University G, AB ACR. OSU6162 in bipolar depression (OBID); 2021. Available from: https://ClinicalTrials.gov/show/NCT05296356. Accessed December 8, 2022.
   Google Scholar
• University JH, Fund BBR, Medical M, Austin UoTa. iTBS in bipolar I depression; 2022. Available from: https://ClinicalTrials.gov/show/NCT05375214. Accessed December 8, 2022.
   Google Scholar
• University of California SF. Psilocybin therapy for depression in bipolar II disorder; 2022. Available from: https://ClinicalTrials.gov/show/NCT05065294. Accessed December 8, 2022.
   Google Scholar
• University Qs, Clinic OP. Delivering electronic cognitive behavioural therapy to patients with bipolar disorder and residual depressive symptoms; 2020. Available from: https://ClinicalTrials.gov/show/NCT04664257. Accessed December 8, 2022.
   Google Scholar
• Brown ES, Khaleghi N, Van Enkevort E, et al. A pilot study of brexpiprazole for bipolar depression. J Affect Disord. 2019;249:315–318. doi:10.1016/j.jad.2019.02.056
   PubMed Web of Science ®Google Scholar
• Calabrese JR, Durgam S, Satlin A, et al. Efficacy and safety of lumateperone for major depressive episodes associated with bipolar I or bipolar II disorder: a phase 3 randomized placebo-controlled trial. Am J Psychiatry. 2021;178(12):1098–1106. doi:10.1176/appi.ajp.2021.20091339
   PubMed Web of Science ®Google Scholar
• Frampton JE. Vortioxetine: a review in cognitive dysfunction in depression. Drugs. 2016;76(17):1675–1682. doi:10.1007/s40265-016-0655-3
   PubMed Web of Science ®Google Scholar
• Gdansk MUo. A naturalistic study of ketamine for treatment resistant mood disorders; 2019. Available from: https://ClinicalTrials.gov/show/NCT04226963. Accessed December 8, 2022.
   Google Scholar
• System SPH, Pathways C. The safety and efficacy of psilocybin in participants with type 2 bipolar disorder (BP-II) depression; 2021. Available from: https://ClinicalTrials.gov/show/NCT04433845. Accessed December 8, 2022.
   Google Scholar
• Carhart-Harris RL, Bolstridge M, Rucker J, et al. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry. 2016;3(7):619–627. doi:10.1016/S2215-0366(16)30065-7
   PubMed Web of Science ®Google Scholar
• Kisely S, Connor M, Somogyi AA, Siskind D. A systematic literature review and meta-analysis of the effect of psilocybin and methylenedioxymethamphetamine on mental, behavioural or developmental disorders. Aust N Z J Psychiatry. 2022;48674221083868. doi:10.1177/00048674221083868
   Web of Science ®Google Scholar
• Hendin HM, Penn AD. An episode of mania following self-reported ingestion of psilocybin mushrooms in a woman previously not diagnosed with bipolar disorder: a case report. Bipolar Disord. 2021;23(7):733–735. doi:10.1111/bdi.13095
   Web of Science ®Google Scholar
• McIntyre RS, Rosenblat JD, Nemeroff CB, et al. Synthesizing the evidence for ketamine and esketamine in treatment-resistant depression: an international expert opinion on the available evidence and implementation. Am J Psychiatry. 2021;178(5):383–399. doi:10.1176/appi.ajp.2020.20081251
   PubMed Web of Science ®Google Scholar
• The University of Texas Health Science Center H. Magnetic seizure therapy in bipolar depression (MST-BpD); 2022. Available from: https://ClinicalTrials.gov/show/NCT04080778. Accessed December 8, 2022.
   Google Scholar
• Bosch OG, Halm S, Seifritz E. Psychedelics in the treatment of unipolar and bipolar depression. Int J Bipolar Disord. 2022;10(1):18. doi:10.1186/s40345-022-00265-5
   Web of Science ®Google Scholar
• Seshadri A, Sundaresh V, Prokop LJ, Singh B. Thyroid hormone augmentation for bipolar disorder: a systematic review. Brain Sci. 2022;12(11):1540. doi:10.3390/brainsci12111540
   Web of Science ®Google Scholar